ArticleMultiple sclerosis and related disorders2020
Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder.
Article in Multiple sclerosis and related disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis.Multiple sclerosis and related disorders · 2022Pooled it
- COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.Multiple sclerosis and related disorders · 2021Pooled it
- Coronavirus disease 2019 and neurodegenerative disease: what will the future bring?Current opinion in psychiatry · 2021Pooled it
- Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review.Clinical neurology and neurosurgery · 2021Pooled it
- Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis.Biomedicines · 2023Article
- Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.Enfermedades infecciosas y microbiologia clinica (English ed.) · 2022Review
- The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?Multiple sclerosis and related disorders · 2022Article
- Mechanism of Multi-Organ Injury in Experimental COVID-19 and Its Inhibition by a Small Molecule Peptide.Frontiers in pharmacology · 2022Article
- Differential modulation of lung aquaporins among other pathophysiological markers in acute (ClFrontiers in physiology · 2022Article
- The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection.Frontiers in immunology · 2022Review
- Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders.Neurology(R) neuroimmunology & neuroinflammation · 2021Observational
- The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review.Iranian journal of medical sciences · 2021Review
- Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.European journal of immunology · 2021Article
- In-silico immunoinformatic analysis of SARS-CoV-2 virus for the development of putative vaccine construct.Immunobiology · 2021Article
- A New England COVID-19 Registry of Patients With CNS Demyelinating Disease: A Pilot Analysis.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Prevalence of coronavirus disease 2019 in patients with neuromyelitis optica in Isfahan, Iran, and a review on recent reports and literature.Current journal of neurology · 2021Article
- [Neuroimmunology of COVID-19].Der Nervenarzt · 2021Review
- Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.Enfermedades infecciosas y microbiologia clinica (English ed.) · 2021Review
- The Impact of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorder Beyond Infection Risk.Frontiers in neurology · 2021Article
- COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review.Pathogens & immunity · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus SARS-CoV-2, which affects the lung and other organs. After an incubation period of 3-14 days, the infection presents with symptoms of variable severity, from mild flu-like disease to severe pneumonia and cytokine storm with increased mortality. Immunosuppressed patients may have higher risk of adverse outcomes; hence, there is an urgent need to evaluate the immune response and clinical outcomes of SARS-CoV-2 infection in these patients. Here, we report a 59-year-old woman with aquaporin-4-positive (AQPR4+) neuromyelitis Optica treated with rituximab who developed mild respiratory symptoms with COVID-19, despite B cell depletion at the time of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.